The Pune Municipal Corporation (PMC) health department had written to the PMC environment department in the last week of ...
Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...
Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Aizawl: At least seven people died out of 16,899 individuals infected with malaria in 2024, officials from Mizoram's National Vector Borne Disease Con.
Health department launches mobile campaign to prevent vector-borne infections like dengue and chikungunya, reaching ...
The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...
With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...
2d
GlobalData on MSNBavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teensBavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results